Healthcare & Medical Devices Global On demand · 24-48h

Global Diagnosing Brain Tumors Market Strategic Research Report

Global Diagnosing Brain Tumors Market Strategic Research Rep…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Diagnosing Brain Tumors Market
$2.99B2025
7.2%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Magnetic Resonance Imaging (MRI), Computed Tomography (C1) Scan, PET Scan, Others

By Application: Hospital, Specialty Clinic, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Rare Diagnostics, Abbott Laboratories, Illumina Inc, Hologic Inc, Agilent Technologies, Bio Rad Laboratories

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 94 pages
Market size 2025
$2.99B
Billion USD
Forecast CAGR
7.2%
2025-2032
Forecast 2032
$4.9B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Diagnosing Brain Tumors market size is predicted to grow from US$ 2,992 million in 2025 to US$ 4,811 million in 2032; it is expected to grow at a CAGR of 7.2% from 2026 to 2032.

Diagnosing brain tumors involves identifying and confirming the presence of abnormal growths or masses in the brain. This process typically requires a combination of medical history assessment, physical examination, and various imaging and laboratory tests.

Continued advancements in imaging technologies, such as functional MRI (fMRI), diffusion tensor imaging (DTI), and spectroscopy, contribute to more precise and detailed imaging of brain structures and abnormalities. These technologies can aid in better characterizing tumor properties and understanding their impact on surrounding tissues.

This report presents a comprehensive overview of the global Diagnosing Brain Tumors market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (C1) Scan
  • PET Scan
  • Others

Segment by Application

  • Hospital
  • Specialty Clinic
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Diagnosing Brain Tumors market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Specialty Clinic, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Diagnosing Brain Tumors Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.2%
Regional growth momentum
Market share by segment
Key metrics
Base value
$2.99B
2025
Forecast
$4.9B
2032
CAGR
7.2%
2025–2032
Regions
5
global
Key companies
GE HealthcareSiemens HealthineersPhilips HealthcareThermo Fisher ScientificRare DiagnosticsAbbott LaboratoriesIllumina IncHologic Inc
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Magnetic Resonance Imaging (MRI)Computed Tomography (C1) ScanPET ScanOthers
By Application
HospitalSpecialty ClinicOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Magnetic Resonance Imaging (MRI)
  • 3.1.3 Computed Tomography (C1) Scan
  • 3.1.4 PET Scan
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Specialty Clinic
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 GE Healthcare
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Siemens Healthineers
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Philips Healthcare
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Thermo Fisher Scientific
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Rare Diagnostics
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Abbott Laboratories
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Illumina Inc
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Hologic Inc
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Agilent Technologies
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Bio Rad Laboratories
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Diagnosing Brain Tumors market?
The global Diagnosing Brain Tumors market is estimated at US$ 2.99 billion in 2025 (base year) and is projected to reach US$ 4.81 billion by 2032.
What is the forecast CAGR for the Diagnosing Brain Tumors market?
The market is expected to grow at a CAGR of 7.2% from 2026 to 2032, expanding from US$ 2.99 billion in 2025 to US$ 4.81 billion in 2032, roughly 1.6 times its base-year value.
What is Diagnosing Brain Tumors?
Diagnosing brain tumors involves identifying and confirming the presence of abnormal growths or masses in the brain. This process typically requires a combination of medical history assessment, physical examination, and various imaging and laboratory tests.
What are the main segments of the Diagnosing Brain Tumors market by type?
By type, the market is segmented into Magnetic Resonance Imaging (MRI), Computed Tomography (C1) Scan, PET Scan and Others.
Which applications drive demand in the Diagnosing Brain Tumors market?
Key applications covered include Hospital, Specialty Clinic and Others.
Who are the key players in the Diagnosing Brain Tumors market?
Key players profiled include GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Rare Diagnostics, Abbott Laboratories, Illumina Inc and Hologic Inc, among 10 companies covered in total.
Which regions and countries are covered for Diagnosing Brain Tumors?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Diagnosing Brain Tumors market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Specialty Clinic and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Diagnosing Brain Tumors market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.